Filtered By:
Cancer: Lymphoma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 25586 results found since Jan 2013.

Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells
Conclusions The combination of BCL11A siRNA and VCR increases apoptosis in SUDHL6 cells. Our study implies that BCL11A siRNA in combination with VCR may be a useful approach for improving effective treatment for B cell lymphoma.
Source: European Journal of Medical Research - June 24, 2014 Category: Research Source Type: research

Co-delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Abstract Development of drug resistance to anticancer drugs is an important challenge for cancer treatment. Recent studies focus on co-delivery of anticancer drugs and siRNA to overcome this challenge. Mesoporous silica nanoparticles (MSNs) are one of the promising nanoparticles that enable the delivery of drugs and siRNA simultaneously. MSNs coated with copolymer that able for co-delivery of drug and siRNA were prepared and characterized. In the present study, MSNs functionalized with polyethylenimine-polyethylene glycol (PEI-PEG) copolymer were prepared. MSNs were characterized using dynamic light scattering (DL...
Source: Current Drug Delivery - December 30, 2015 Category: Drugs & Pharmacology Authors: YahyaHanafi-Bojd M, Jaafari MR, Ramezanian N, Abnous K, Malaekeh-Nikouei B Tags: Curr Drug Deliv Source Type: research

B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy
Conclusions: Peptide-siRNA complex can be suitable tool for both selective peptide-driven cell targeting and gene silencing. In this setting, the improvement of this strategy is expected to provide a safe and non-invasive approach for the delivery of therapeutic molecules.
Source: Cancer Cell International - May 7, 2015 Category: Cancer & Oncology Authors: Nunzia MigliaccioCamillo PalmieriImmacolata RuggieroGiuseppe FiumeNicola MartucciIris ScalaIleana QuintoGiuseppe ScalaAnnalisa LambertiPaolo Arcari Source Type: research

Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.
Authors: Huo L, Wei W, Wu S, Zhao X, Zhao C, Zhao H, Sun L Abstract The effectiveness of therapy combining dihydroartemisinin (DHA) and small interfering RNA targeting Notch1 (siNotch1) in T-cell lymphoma remains unknown. The present study explored the potential and possible mechanisms of combined dihydroarteminin, and siNotch1 therapy for T-cell lymphoma. It was demonstrated that the viability rates of siRNA-DHA-treated cells was significantly suppressed in comparison with those in control cells, control siRNA cells, siRNA-treated cells and DHA-treated cells (P<0.01). Additionally, there was a significant incre...
Source: Experimental and Therapeutic Medicine - March 31, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma
Clinical applications of siRNA therapeutics have been limited by the immunogenicity of the siRNA and low efficiency of siRNA delivery to target cells. Recently, evidence have shown that exosomes, endogenous nano-vesicles, can deliver siRNA to the tumor tissues in mice. Here, to reduce immunogenicity, we selected immature dendritic cells (DCs) to produce exosomes. In addition, tumor targeting was achieved by engineering the DCs to express exosomal membrane protein (Lamp2b), fused to av integrin-specific iRGD peptide (CRGDKGPDC). Next, iRGD targeted exosomes (iRGD-Exo) were isolated from the transfected DCs, and then the iso...
Source: Frontiers in Oncology - August 2, 2022 Category: Cancer & Oncology Source Type: research

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Intracellular therapeutic targets that define tumor immunosuppression in both tumor cells and T cells remain intractable. Here, we have shown that administration of a covalently linked siRNA to an aptamer (apt) that selectively binds cytotoxic T lymphocyte–associated antigen 4 (CTLA4apt) allows gene silencing in exhausted CD8+ T cells and Tregs in tumors as well as CTLA4-expressing malignant T cells. CTLA4 expression was upregulated in CD8+ T cells in the tumor milieu; therefore, CTLA4apt fused to a STAT3-targeting siRNA (CTLA4apt–STAT3 siRNA) resulted in internalization into tumor-associated CD8+ T cells and silencing...
Source: Journal of Clinical Investigation - June 3, 2014 Category: Biomedical Science Authors: Andreas Herrmann, Saul J. Priceman, Maciej Kujawski, Hong Xin, Gregory A. Cherryholmes, Wang Zhang, Chunyan Zhang, Christoph Lahtz, Claudia Kowolik, Steve J. Forman, Marcin Kortylewski, Hua Yu Source Type: research

Gene expression profile analysis of SUDHL6 cells with siRNA-mediated BCL11 A downregulation.
Abstract Our previous study has shown that downregulation of B-cell chronic lymphocytic leukemia (CLL)/lymphoma11A (BCL11A) gene by small interfering RNA (siRNA) results in the growth inhibition and apoptosis of B cell lymphoma cell line SUDHL6. To gain further insight into the molecular mechanisms of this process and identify the differentially expressed genes in SUDHL6 cells after BCL11A downregulation, the global gene expression profile was identified and analyzed using the Affymetrix HG-U133 Plus 2.0 array.Twenty-one differentially expressed genes were validated and analyzed from the BCL11 A siRNA-treated SUDH...
Source: Cell Biology International - July 7, 2014 Category: Cytology Authors: Wu H, Li Y Tags: Cell Biol Int Source Type: research

Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents
In conclusion, the simultaneous treatment of lung cancer cells with ABCE1 siRNA and 5-FU exhibited synergistic or additive effects; however, ABCE1 siRNA and irinotecan had unexpected antagonistic effects. Our findings demonstrate that the strategy of downregulation of ABCE1 may be included in conventional 5-FU chemotherapy for lung cancer, minimizing the usage of 5-FU at high dosages.
Source: Medical Oncology - March 6, 2015 Category: Cancer & Oncology Source Type: research

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
In this study we aim to develop pegylated siRNA lipoplexes formed using the cationic lipid DOTAP and DSPE-PEG2000, capable to effectively stabilize anti Blimp-1 siRNA and suitable for systemic administration. Two types of pegylated lipoplexes using a classic (C-PEG Lipoplexes) or a post-pegylation method (P-PEG-Lipoplexes) were formulated and compared in their physicochemical properties (size, zeta potential, morphology and structure) and efficiency on PEL cell lines. A stable siRNAs protection was obtained with post pegylation approach (2% molar of DSPE-PEG2000 respect to lipid) resulting in structures with diameters of 3...
Source: European Journal of Pharmaceutics and Biopharmaceutics - November 25, 2015 Category: Drugs & Pharmacology Authors: Belletti D, Tosi G, Forni F, Lagreca I, Barozzi P, Pederzoli F, Vandelli MA, Riva G, Luppi M, Ruozi B Tags: Eur J Pharm Biopharm Source Type: research

Surface-Functionalized Polymeric siRNA Nanoparticles for Tunable Targeting and Intracellular Delivery to Hematologic Cancer Cells
Biomacromolecules. 2022 Apr 1. doi: 10.1021/acs.biomac.1c01497. Online ahead of print.ABSTRACTTo date, the application of RNA therapeutics to hematologic malignancies has been challenging owing to the resistance of blood cancer cells against conventional transfection methods. Herein, triple-targeting moiety-functionalized polymeric small interfering RNA (siRNA) nanoparticles were systematically developed for efficient targeted delivery of RNA therapeutics to hematologic cancer cells. Polymeric siRNAs were synthesized using rolling circle transcription and were surface-functionalized with three types of targeting moietiesâ”...
Source: Biomacromolecules - April 1, 2022 Category: Biochemistry Authors: Eunji Kwak Taehyung Kim Kyungjik Yang Young Min Kim Hwa Seung Han Kyung Hoon Park Ki Young Choi Young Hoon Roh Source Type: research

Lentiviral Vector-Mediated siRNA Knockdown of c-MYC: Cell Growth Inhibition and Cell Cycle Arrest at G2/M Phase in Jijoye Cells.
Abstract Inhibition of c-MYC has been considered as a potential therapy for lymphoma treatment. We explored a lentiviral vector-mediated small interfering RNA (siRNA) expression vector to stably reduce c-MYC expression in B cell line Jijoye cells and investigated the effects of c-MYC downregulation on cell growth, cell cycle, and apoptosis in vitro. The expression of c-MYC mRNA and protein levels were inhibited significantly by c-MYC siRNA. The c-MYC downregulation resulted in the inhibition of cell proliferation and cell cycle arrest at G2/M phase, which was associated with decreased expression of cyclin B and cy...
Source: Biochemical Genetics - May 9, 2013 Category: Genetics & Stem Cells Authors: Song A, Ye J, Zhang K, Sun L, Zhao Y, Yu H Tags: Biochem Genet Source Type: research

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Abstract Success of an immunotherapy for cancer often depends on the critical balance of T helper 1 (Th1) and T helper 2 (Th2) responses driven by antigen presenting cells, specifically dendritic cells (DCs). Th1-driven cytotoxic T cell (CTL) responses are key to eliminating tumor cells. It is well established that CpG oligonucleotides (ODN), a widely studied Toll-like receptor 9 (TLR9) agonist, used to enhance Th1 response, also induces high levels of the anti-inflammatory, Th2-promoting cytokine IL10, which could dampen the resulting Th1 response. Biomaterials-based immunomodulatory strategies that can reduce IL...
Source: Biomaterials - April 7, 2014 Category: Materials Science Authors: Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K Tags: Biomaterials Source Type: research

Methods for Assembling B-Cell Lymphoma Specific and Internalizing Aptamer–siRNA Nanoparticles Via the Sticky Bridge
Structured functional RNA entities, including aptamers and siRNAs, have amazing versatility in structure and function. These molecules can serve as powerful, attractive building blocks for the bottom-up assembly of complex nanostructures. Here, we describe novel cell-type specific and internalizing B-cell activating factor receptor (BAFF-R) aptamer–siRNA delivery systems for B-cell lymphoma therapy, in which both the aptamer and the Dicer substrate siRNA (DsiRNA) portions are conjugated through a “sticky bridge.” The BAFF-R is overexpressed on the surface of B-cell malignancies, allowing binding and inter...
Source: Springer protocols feed by Biotechnology - April 25, 2015 Category: Biotechnology Source Type: news